RSV-NET data showed that RSV hospitalization rates among infants aged 0 to 7 months were an estimated 43% (95% confidence ...

CDC data showed a drop in the infant mortality rate in 2024, compared to the previous year. Pfizer's maternal vaccine, sold ...

Widespread use of maternal RSV vaccination and nirsevimab during the 2024–2025 U.S. RSV season led to a significant reduction ...

Of the RSV patients aged 60 or older, 23.0% were admitted to an ICU, 31.5% had acute organ failure, and 9.8% received IMV or ...

Interim surveillance network data showed lower hospitalization rates following the availability of prevention products.

There was a significant drop in the number of babies hospitalized with RSV this year; a positive news story that can be ...

Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated ...

The U.S. Centers for Disease Control and Prevention has accepted its advisory panel's recommendations on vaccines for ...

The Centers for Disease Control and Prevention May 8 released an analysis that found declines in hospitalizations for infants infected with respiratory syncytial virus during the 2024-2025 RSV season.

A 2024-25 flu season that has been classified as high severity has now reached low transmission levels, but 10 new ...

Maternal RSV vaccination and nirsevimab were associated with a reduction in RSV hospitalization rates in infants aged 0 to 7 months during the 2024-2025 RSV season.